Treatment of Subarachnoid Hemorrhage With Human Albumin
Information source: Baylor College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Subarachnoid Hemorrhage
Intervention: 25% human albumin (Drug)
Sponsored by: Baylor College of Medicine
Official(s) and/or principal investigator(s):
Jose I. Suarez, MD, Principal Investigator, Affiliation: Baylor College of Medicine
The purpose of this study is to evaluate the tolerability and safety of 25 percent human
albumin therapy in patients with subarachnoid hemorrhage.
Official title: Treatment of Subarachnoid Hemorrhage With Human Albumin
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Safety and Tolerability of the 25% Human Albumin Dosages and the Functional Outcome.
Serious Adverse Events
Good Clinical Outcome Was Defined as a Glasgow Outcome Scale Score of 0-1
An estimated 37,500 people in the United States have subarachnoid hemorrhage (SAH) every
year. SAH is usually secondary to a brain aneurysm that has burst. In SAH the bleeding
accumulates around the lining of the brain. SAH is associated with a 51percent mortality
rate, and one third of survivors are left functionally dependent. Cerebral vasospasm, which
is a delayed narrowing of the cerebral arteries following SAH, has been identified as the
most important reason for neurological deterioration and bad outcome in cases of SAH.
Cerebral vasospasm may be caused by multiple mechanisms.
Treatment with a neuroprotective agent, such as human albumin (HA), may be beneficial for
prevention of cerebral vasospasm and improved clinical outcome in patients with SAH. HA is
a major protein found in blood and is responsible for maintaining fluid balance in the
vascular system (blood vessels). The purpose of this study was to determine the safety and
tolerability of 25 percent HA therapy in patients with SAH. This open-label,
dose-escalation study will provide necessary information for a future definitive phase III
clinical trial on the efficacy of treatment with HA in patients with SAH.
The study was designed to enroll 80 patients at 5 centers in the US. Patients with eligible
SAH first underwent surgical or endovascular repair, which was considered standard care.
Endovascular repair was a repair of the aneurysm from the inside of the blood vessel.
Following neurosurgical or endovascular treatment, participants were given a daily infusion
of HA for 7 days. The HA dose was allocated as follows: the first tier (20 patients) would
receive 0. 625 grams (g) of HA per kilogram (kg) of body weight; patients in the second tier
would receive 1. 25g of HA per kg; patients in the third tier would receive 1. 875g of HA per
kg; and patients in the fourth tier would receive 2. 5g of HA per kg. Safety and
tolerability was evaluated by the Data and Safety Monitoring Board (DSMB) after each tier
was completed and before the study advanced to the next dose tier. A specific safety
threshold for congestive heart failure and other adverse events was defined based on data
from previous studies.
In the follow-up phase, patients participated in study-related evaluations of their health
at 15 days and three months. Duration of the study for participants was 90 days.
Minimum age: 18 Years.
Maximum age: 79 Years.
- Patients (male or female) were at least 18 but younger than 80 years of age.
- Onset of new neurological signs of subarachnoid hemorrhage within 72 hours at the
time of evaluation and initiation of treatment with 25% human albumin.
- Clinical signs consistent with the diagnosis of subarachnoid hemorrhage including
severe thunderclap headache, cranial nerve abnormalities, decreased level of
consciousness, meningismus and focal neurological deficits.
- Computed tomography demonstrated subarachnoid hemorrhage.
- Cerebral angiography revealed the presence of saccular aneurysm(s) in a location that
explains the subarachnoid hemorrhage.
- Treatment of cerebral aneurysm was carried out prior to initiation of HA infusion but
within 72 hours of symptom onset. Accepted treatments of aneurysms include surgical
clipping or endovascular embolization.
- Time of symptom onset could be reliably assessed.
- No demonstrable aneurysm by cerebral angiography.
- Evidence of traumatic, mycotic, or fusiform aneurysm by cerebral angiography.
- World Federation of Neurological Surgeons scale of IV and V
- Computed tomography scale of 0-1
- History within the past 6 months, and/or physical findings on admission of
decompensated congestive heart failure (NYHA Class IV or congestive heart failure
- Patient received albumin prior to treatment assignment during the present admission.
- Hospitalization for or diagnosis of acute myocardial infarction within the preceding
- Symptoms or electrocardiographic signs indicative of acute myocardial infarction on
- Electrocardiographic evidence and/or physical findings compatible with second- or
third-degree heart block, or of cardiac arrhythmia associated with hemodynamic
- Echocardiogram performed before treatment revealing a left ventricular ejection
fraction ≤ 40% (if available).
- Serum creatinine > 2. 0 mg/dl or creatinine clearance < 50 ml/min.
- Pregnancy, lactation or parturition within previous 30 days.
- Allergy to albumin.
- Severe prior physical disability that precludes evaluation of clinical outcome
- History of chronic lung disease
- Current participation in another drug treatment protocol.
- Severe terminal disease with life expectancy less than 6 months.
Locations and Contacts
University of Calgary, Calgary, Alberta, Canada
The Johns Hopkins Hospital, Baltimore, Maryland 21287, United States
University of Toronto, Toronto, Ontario, Canada
Penn State University, Hershey, Pennsylvania 17033, United States
Data Coordination Unit, Department of Biostatistics, Bioinformatics and Epidemiology, at the Medical University of South Carolina, Charleston, South Carolina 29425, United States
Baylor College of Medicine, Houston, Texas 77030, United States
Suarez JI, Shannon L, Zaidat OO, Suri MF, Singh G, Lynch G, Selman WR. Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage. J Neurosurg. 2004 Apr;100(4):585-90.
Suarez JI, Qureshi AI, Yahia AB, Parekh PD, Tamargo RJ, Williams MA, Ulatowski JA, Hanley DF, Razumovsky AY. Symptomatic vasospasm diagnosis after subarachnoid hemorrhage: evaluation of transcranial Doppler ultrasound and cerebral angiography as related to compromised vascular distribution. Crit Care Med. 2002 Jun;30(6):1348-55.
Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, Raps EC, Solomon RA. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial. Stroke. 2000 Feb;31(2):383-91.
Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993 Apr;78(4):537-47.
Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001 Aug 7;135(3):149-64.
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 May 27;350(22):2247-56.
Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001 Feb;32(2):553-60.
Osterloh K, Ewert U, Pries AR. Interaction of albumin with the endothelial cell surface. Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H398-405.
Zhang WJ, Frei B. Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002 Sep;55(4):820-9.
Starting date: January 2006
Last updated: March 18, 2015